Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LATA: Long-Acting Treatment in Adolescents
NCT05154747Phase 3Active, not recruiting
- Sponsor
- University College London
- Start
- Jun 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of cabotegravir, rilpivirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by University College London. Started Jun 2023; status: active, not recruiting.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05154747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05154747.